References:
  1. Herman P, Fonseca GM, Kruger JAP, Jeismann VB, Coelho FF. Guidelines for the Treatment of Hepatocellular Adenoma in the Era of Molecular Biology: An Experience-Based Surgeons’ Perspective. J Gastrointest Surg 2021;25(6):1494-502.
  2. Agha RA, Borrelli MR, Farwana R, Koshy K, Fowler A, Orgill DP, For the SCARE Group. The SCARE 2018 Statement: Updating Consensus Surgical CAse REport (SCARE) Guidelines. Int J Surg 2018;60:132-6.
  3. Fukayama M, Paradis V, Park YN, Schirmacher P. WHO Classification of Tumours of the Digestive System. 8. Tumours of the liver and intrahepatic bile ducts. Fifth ed. Geneva: World Health Organization; 2019.
  4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of benign liver tumours. J Hepatol 2016;65:386-98.
  5. Mounajjed T. Hepatocellular adenoma and Focal nodular Hyperplasia. Clin liver Dis 2021;17(4):244-8.
  6. Neves Sousaa CM, de Sousa Cartaxoa R, Schuler Honorio R, Rêgo Coelhod G, Rêgo Coelhoa C, Miranda Gadelhaa PM, et al. Hepatocyte Nuclear Factor 1α-Mutated Hepatocellular Adenomas: An Atypical Presentation. Case Rep Gastroenterol 2017;11:637-42.
  7. Vincenzo K. Wong VK, Fung AW, Elsayes KM. Magnetic resonance imaging of Hepatic adenoma subtypes. Clin liver Dis 2021;17(3):113-8.
  8. Wong VK, Fung AW, Elsayes KM. Magnetic resonance imaging of Hepatic adenoma subtypes. Clin liver Dis 2021;17(3):113-8.
  9. Beaufrère A, Paradis V. Hepatocellular adenomas: review of pathological and molecular features. Hum Pathol 2020.https://doi.org/10.1016/j. humpath.2020.11.016.
  10. Védie AL, Sutter O, Ziol M, Nault JC. Molecular classification of hepatocellular adenomas: impact on clinical practice. Hepat Oncol 2018;5(1):HEP04.
  11. Garcia-Buitrago MT. Advances in hepatology. Gastroenter Hepatol 2017;13(12):740-3.
  12. Bieze M, van den Esschert JW, Nio CY, Verheij J, Reitsma JB, Terpstra V, et al. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR 2012;199:26-34.
  13. Auer TA, Fehrenbach U, Grieser C, Penzkofer T, Geisel D, Schmelzle M, Müller T, Bläker H, Seehofer D, Denecke T. Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation? Eur Radiol 2020;30:3497-506.
  14. van Aalten SM, Thomeer MG, Terkivatan T, et al. Hepatocellular ade- nomas: correlation of MR imaging findings with pathologic subtype classification. Radiology 2011;261:172-81.
  15. Koya Y, Suzuki T, Tai M, Ichii O, Matsuhashi N, Ejiri Y, et al. Inflammatory Hepatocellular Adenoma with Elevated Serum Protein Induced by Vitamin K Absence/Antagonist-II in Adult Males. Intern Med 2019;58:1739-46.
  16. Hoshino K, Harimoto N, Muranushi R, Hagiwara K, Yamanaka T, Ishii N, et al. Unclassified hepatocellular adenoma with histological brown pigment deposition and serum PIVKA-II level elevation: a case report. Surg Case Rep 2020;6:94.
  17. Fodor M, Primavesi F, Braunwarth E, Cardini B, Resch T, Bale R, et al. Indications for liver surgery in benign tumours. Eur Surg 2018;50:125-31.
  18. Kim SM, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, et al. Clinicopathological features and post-resection outcomes of hepatocellular adenoma. Ann Hepatobiliary Pancreat Surg 2021;25:25-33.
  19. van Rosmalen BV, Klompenhouwer AJ, Jaap de Graeff J, Haring MDP, de Meijer VE, Rifai L, et al. Safety and efficacy of transarterial embolization of hepatocellular adenomas. BJS 2019;106:1362-71.